Bepirovirsen (Hibsago) Hepatitis B: USMLE Review

The FDA has approved Hibsago (bepirovirsen) for certain adults with chronic hepatitis B. It is the first drug of its kind for this infection. In two clinical trials, a minority of patients reached a "functional cure," meaning they could stop all hepatitis B medication while the virus stayed controlled. Despite some headlines, this is a subcutaneous injection and not a vaccine.

What happened

The FDA approved Hibsago on a Tuesday for a narrow group of adults. According to the source report, eligible patients:

• do not have cirrhosis,
• have taken antiviral medicine for at least six months,
• have suppressed virus, and
• have low levels of hepatitis B surface antigen (HBsAg).

Patients receive Hibsago as a shot under the skin for up to six months, in addition to their usual antiviral. After the first dose, they can choose to inject themselves, according to GSK, the manufacturer. Once patients have been off the shots for six months, those who meet certain health and lab requirements may be able to stop their regular medicine.

The numbers come from two clinical trials, as reported by the FDA:

• 24% of patients given Hibsago met the requirements to stop their regular therapy. None of the placebo recipients did.
• 19% of Hibsago patients were still controlling the virus six months after stopping all hepatitis B treatment, with HBsAg not detectable in their blood.

GSK calls this result a "functional cure," meaning the immune system controls the infection without medicine. The source notes that the Hepatitis B Foundation says there is still no complete cure for hepatitis B.

Why it matters: chronic hepatitis B and the end of lifelong therapy

Standard treatment today is a daily antiviral pill, typically for more than a year, according to the Hepatitis B Foundation. For many people it continues for years to keep the virus suppressed. Chronic infection can scar the liver (cirrhosis) and raise the risk of liver cancer. GSK estimates about 1.7 million people in the United States have the infection.

Existing antivirals suppress replication, but they rarely lead to loss of HBsAg. That is why a finite course of treatment with a chance of stopping all medication is notable. Dr. Norah Terrault of USC's Keck Medical Center called the approval "the start of a new era" and described functional cure after a short treatment course as a long-standing goal.

The drug works differently from antiviral pills. According to the source, it disrupts the genetic messages the virus needs to multiply. Drugs that target RNA in this way follow the antisense or RNA-interference logic you may have seen in pharmacology. The source does not give further mechanistic detail, so do not over-read it.

What to know for the USMLE: HBV, HBsAg, and functional cure

• Virus basics: HBV is a partially double-stranded DNA virus (Hepadnaviridae) that replicates through an RNA intermediate using reverse transcriptase. After infection, the genome forms cccDNA in hepatocyte nuclei. This persistent template is a classic explanation for why antivirals suppress but rarely eradicate the virus.
• Serology pattern:
• HBsAg marks current infection. Persistence for more than 6 months defines chronic infection.
• Anti-HBs alone indicates vaccination or resolved infection with immunity.
• IgM anti-HBc marks acute infection and may be the only positive marker in the "window period."
• Total anti-HBc (IgG) signals past or chronic exposure and is not produced by vaccination.
• HBeAg and HBV DNA reflect replication and infectivity.
• Functional cure means sustained HBsAg loss with undetectable viral replication off treatment. It is not eradication, because cccDNA can persist. Keep the term distinct from "complete cure."
• Standard first-line oral drugs are the nucleos(t)ide analogs entecavir and tenofovir (TDF or TAF). They inhibit the viral polymerase/reverse transcriptase and have a high barrier to resistance. Lamivudine is an older agent with higher resistance rates. Peginterferon alfa is an immunomodulatory alternative with a finite course but more side effects.
• Monitoring: HBV DNA (viral load), ALT, and HBsAg. Patients with cirrhosis or high-risk features need hepatocellular carcinoma surveillance, typically ultrasound with or without AFP.
• Reactivation: HBV can reactivate with immunosuppression such as rituximab, high-dose steroids, or chemotherapy. Exam questions often ask which patients to screen with HBsAg and anti-HBc before such therapy.
• Complications to link: cirrhosis, portal hypertension, HCC, and extrahepatic immune-complex disease such as polyarteritis nodosa and membranous or membranoproliferative glomerulonephritis. HDV coinfection requires HBsAg and worsens disease.
• Prevention: the vaccine is a recombinant HBsAg product. Hibsago is a treatment and has nothing to do with the vaccine.
• Boxed-warning logic: the label warns of severe liver reactions and thrombocytopenia with life-threatening bleeding. Recall that platelets support primary hemostasis, so a low count presents with mucosal bleeding, petechiae, and prolonged bleeding time with normal PT and PTT. Cirrhosis can also cause thrombocytopenia through splenic sequestration and reduced thrombopoietin, so keep the differential broad.
• Flares after stopping therapy: a rise in ALT when antivirals are withdrawn is a recognized phenomenon. The source does not discuss it for this drug, but it is why monitoring after cessation matters conceptually.

Limitations

• Only a minority benefit. In the trials, 24% met the criteria to stop therapy and 19% remained controlled six months after stopping. Most treated patients did not reach this outcome.
• Short follow-up. The reported endpoint is six months off all therapy. The source gives no data on durability beyond that.
• Narrow eligibility. The drug is approved only for adults without cirrhosis whose virus is already suppressed and whose HBsAg is low. It is not a treatment for everyone with hepatitis B.
• Serious risks. The boxed warning covers severe liver reactions and low platelets with possible life-threatening bleeding. Frequent blood work is required before and during treatment.
• Missing details. The source does not give trial sizes, participant characteristics, or full safety rates. Those are in the FDA documents and should be checked there.
• Secondary reporting. This article relies on a news report that cites the FDA and GSK. The manufacturer's "functional cure" label is its own term. The Hepatitis B Foundation notes there is still no complete cure.

This article is educational and is not medical advice for any individual.

FAQ

Is Hibsago a hepatitis B vaccine?

No. Some headlines call it a "shot," but it is a treatment for adults who already have chronic hepatitis B. Prevention uses the recombinant HBsAg vaccine, which is a separate topic.

What does "functional cure" mean for hepatitis B?

GSK uses it to mean the immune system controls the infection without medicine. In the trials, it meant that virus stayed controlled and HBsAg was undetectable six months after stopping all treatment. It is not the same as a complete cure.

What are the main safety warnings?

The label carries a boxed warning for severe liver reactions and for low platelet counts that can lead to life-threatening bleeding. Patients need frequent blood tests before and during treatment.

Key takeaways

• The FDA approved bepirovirsen (Hibsago) for adults with suppressed chronic hepatitis B, low HBsAg, and no cirrhosis. It is given as a subcutaneous shot for up to six months alongside usual antivirals.
• In two trials, 24% met the criteria to stop standard therapy, and 19% still had virus control and undetectable HBsAg six months after stopping all treatment. No placebo patients met the criteria.
• For the USMLE, review HBV serology, nucleos(t)ide analogs, the meaning of functional cure, HCC surveillance, and reactivation risk. The drug carries boxed warnings for severe liver reactions and thrombocytopenia.